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Intrathecal (i.t.) administration of pituitary adenylate cyclase-activating polypeptide (PACAP) induces
long-lasting nociceptive behaviors for more than 60 min in mice, while the involvement of PACAP type1
receptor (PAC1-R) has not been clariﬁed yet. The present study investigated signaling mechanisms of the
PACAP-induced prolonged nociceptive behaviors. Single i.t. injection of a selective PAC1-R agonist,
maxadilan (Max), mimicked nociceptive behaviors in a dose-dependent manner similar to PACAP. Pre- or
post-treatment of a selective PAC1-R antagonist, max.d.4, signiﬁcantly inhibited the nociceptive behav-
iors by PACAP or Max. Coadministration of a protein kinase A inhibitor, Rp-8-Br-cAMPS, a mitogen-
activated protein kinase/extracellular signal-regulated kinase (ERK) kinase inhibitor, PD98059 or a c-
Jun N-terminal kinase (JNK) inhibitor, SP600125, signiﬁcantly inhibited the nociceptive behaviors by
Max. Immunohistochemistry and immunoblotting analysis revealed that spinal administration of Max-
induced ERK phosphorylation and JNK phosphorylation, and also augmented an astrocyte marker, glial
ﬁbrillary acidic protein in mouse spinal cord. Furthermore, an astroglial toxin, L-a-aminoadipate,
signiﬁcantly attenuated the development of the nociceptive behaviors and ERK phosphorylation by Max.
These results suggest that the activation of spinal PAC1-R induces long-lasting nociception through the
interaction of neurons and astrocytes.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Pituitary adenylate cyclase-activating polypeptide (PACAP),
which shares 68% homology with vasoactive intestinal polypeptide
(VIP), is a pleiotropic neuropeptide, belonging to the VIP/secretin/
glucagon superfamily (1e3). PACAP receptor consists of three
distinct G-protein-coupled receptors: the PACAP-speciﬁc receptor,
PAC1-R, which is mainly coupled to adenylate cyclase/protein ki-
nase A (PKA) and phospholipase C (PLC)/protein kinase C (PKC)
pathways, and the PACAP/VIP-indifferent receptors, VPAC1- and: þ81 99 265. 8567.
c.jp (A. Miyata).
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d/4.0/).VPAC2-R, which are primarily coupled to adenylate cyclase (3,4).
PAC1-R is particularly abundant in central nervous system (CNS)
including spinal dorsal horn (3,5,6), where PACAP-immunoreactive
(IR) ﬁbers are also considerably localized (7e10). These ﬁbers are
thought to be predominantly primary afferents in origin, since
capsaicin treatment releases PACAP from rat spinal cord (11,12) and
induces a signiﬁcant decrease in the number of PACAP-IR nerve
ﬁbers within the spinal cord (7). Furthermore, PACAP mRNA/
immunoreactivity is localized primarily in calcitonin-gene-related
peptide- or substance P (SP)-IR containing neurons in rat dorsal
root ganglion (DRG) (7,13) and is markedly upregulated in periph-
eral nerve injury or inﬂammation (14e18). Together with other
lines of evidence, these suggest that PACAP-PAC1-R system could
play an important role in the modulation of spinal nociceptive
transmission (19). However, the functional signiﬁcance of PAC1-Rnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
T. Ohnou et al. / Journal of Pharmacological Sciences 130 (2016) 194e203 195and its downstream signaling mechanism for spinal nociceptive
transmission has not been completely understood yet.
Previously, we reported that intrathecal (i.t.) injection of PACAP-
induced nociceptive behaviors, which gradually increased after
relatively long latency (2e3 min), and reached to the maximum
around 7e10 min, then lasting for more than 60 min. On the other
hands, in the case of SP, nociceptive behaviors were induced
immediately after the i.t. injection within 15 s, quickly reached to
the maximum and then disappeared almost within 1 min (20).
To understand the nature of the PACAP-induced nociceptive
behaviors, we attempted to clarify the role of PACAP receptor and
its downstream signaling in the nociception using PAC1 speciﬁc
agonist, maxadilan (Max) and PAC1 speciﬁc antagonist, max.d.4
(4,21e24).
2. Materials and methods
2.1. Animals
Male ddY mice (6e12 weeks old) were purchased from Kyudo
Co. Ltd. (Kumamoto, Japan) and housed under controlled temper-
ature (24 ± 1 C) and humidity (55 ± 10%) with a 12-h lightedark
cycle with food and water freely available. The animal experiments
were approved by the Animal Care Committee of Kagoshima Uni-
versity (approval no. MD 12059), and were conducted in accor-
dancewith the ethical guidelines for the study of experimental pain
in conscious animals of the International Association for the Study
of Pain.
2.2. Intrathecal injection and behavioral observation
I.t. injection was given in a volume of 5 ml by percutaneous
puncture through an intervertebral space at the level of the 5th or
6th lumbar vertebra, according to a previously reported procedure
(25).
Before i.t. injection, mice were placed and habituated in a glass
cylinder (414 18 cm)with a ﬁlter paper at the bottomover 20min
immediately after i.t. injection, the mice were placed again in the
same glass cylinder and the number of nociceptive behaviors
consisting of licking, biting and scratching directed toward the
caudal part of the body was counted every 1 min. The cumulative
number of events was pooled over 5 min bins or 30 min period of
observation, and analyzed (20).
2.3. Drugs
Max and max.d.4 were kindly donated from Dr. Tajima (Shi-
seido, Japan) (21e24). PACAP (38-amino acid form) and VIP were
purchased from Peptide Institute Inc. (Osaka, Japan). Rp-8-Br-
cAMPS and L-a-aminoadipate were obtained from Sigma (St. Louis,
MO, USA). PD98059 and SP600125 were from Millipore (Billerica,
MA, USA). These drugs were administrated at the designated con-
centration in artiﬁcial cerebrospinal ﬂuid (ACSF: NaCl 138 mM, KCl
3 mM, CaCl2 1.25 mM, MgCl2 1 mM, D-glucose 1 mM).
2.4. Immunohistochemistry
Immunohistochemistry was performed as previously described
(26). Brieﬂy, the animals were deeply anesthetized with sodium
pentobarbital (60 mg/kg, i.p.) and perfused intracardially with
heparinized saline followed by 4% paraformaldehyde in 0.1 M
phosphate buffer (pH 7.4). After laminectomy the spinal cord
(L3eL5) was identiﬁed, excised and postﬁxed over night at 4 C in
the same ﬁxative, and then replaced sequentially with 10, 15 and
20% sucrose in 0.1 M phosphate buffered saline (PBS) at 4 C forcryoprotection. Transverse spinal sections (30 mm) were cut on a
cryostat and collected in PBS at 4 C to be processed immunohis-
tochemically as free-ﬂoating sections.
Sections were blocked in PBS containing 1% normal donkey
serum (ImmunoBioScience, Mukilteo, WA, USA) for 1 h at room
temperature (RT), and incubated over night at 4 C with the pri-
mary antibodies against phospho-p44/42 MAPK (ERK1/2) (Thr202/
Tyr204) antibody (rabbit,1:100, Cell Signaling Technology, Danvers,
MA, USA) and glial ﬁbrillary acid protein (GFAP) antibody (mouse
monoclonal, 1:500, Millipore). The sections were then incubated
for 1 h at RT with Alexa Fluor 568-labeled donkey anti-rabbit IgG
antibody and Alexa Fluor 488-labeled donkey anti-mouse IgG
antibody (Invitrogen, Carlsbad, CA). Stained sections were exam-
ined with a Zeiss LSM 700 confocal microscope (Carl Zeiss Micro-
scopy, Jena, Germany).
2.5. Western blot analysis
Western blotting was performed as previously described (26).
Brieﬂy, after sacriﬁce of mice, the lumbar spinal cords (L3eL6) were
quickly removed and homogenized in a lysis buffer [150 mM NaCl,
1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and
50 mM TriseHCl, pH 8.0] with a mixture of protease and phos-
phatase inhibitors (Roche Diagnostics, Mannheim, Germany). After
the centrifugation at 13,000 g for 10 min at 4 C, the protein
concentrations of the supernatants were determined with a Bio-
Rad protein assay kit (Bio-Rad, Hercules, CA). The proteins (12 mg)
were separated by SDS-PAGE (12.5% gel) and then transferred onto
polyvinylidene diﬂuoride membrane (Millipore, Billerica, MA).
Following antibodies were used. Anti-p44/42 MAPK (ERK1/2)
(Thr202/Tyr204) (rabbit, 1:1000), anti-phospho-p44/42 MAPK
(ERK1/2) (Thr202/Tyr204) (rabbit, 1:1000), anti-SAPK/JNK (rabbit,
1:1000), and anti-phospho-SAPK/JNK (Thr183/Tyr185) antibodies
(rabbit, 1:1000) were obtained from Cell Signaling. Mouse anti-
GFAP monoclonal antibody (1:10,000) is from Millipore. Immuno-
reactivity was detected by using an ECL prime kit (GE Healthcare,
Buckinghamshire, UK). An anti-b-actin antibody (mouse mono-
clonal, 1:1000; Santa Cruz) was used to normalize protein loading.
Relative intensities of the bands were quantiﬁed by using an image
analysis system with ImageJ software, version 1.46 (National In-
stitutes of Health, Bethesda, MD). At least two independent
immunoblot experiments of two individual spinal cord samples
were analyzed.
2.6. Statistical analysis
Experimental data are expressed as mean ± standard error of
the mean (SEM). Single comparisons were made using Student's
two-tailed unpaired t-test. One- or two-way analysis of variance
followed by the Dunnett's test was used for multiple comparisons.
P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Maxadilan, a selective PAC1-R agonist, induces dose-dependent
long-lasting nociceptive behaviors via PAC1 receptor-PKA signaling
After single i.t. administration of Max, nociceptive behaviors
such as licking and biting, which directed toward the caudal part of
the body, gradually appeared at 3e5 min, reached to the plateau
within 15e20 min, and maintained at least more than 30 min
(Fig. 1A) as well as PACAP-induced nociceptive behaviors described
previously (20). This aversive response subsided within 24 h after
injection (data not shown). Max dose-dependently induced the
nociception, although VIP did not (Fig. 1A and B).
Fig. 1. The effect of a single intrathecal (i.t.) injection of maxadilan (Max) on nociceptive behaviors. (A) Time-dependent and dose-dependent effects of Max (5e50 pmol)-induced
nociceptive behaviors. The cumulative number of events was pooled over 5 min bins. Statistical analysis using two-way repeated-measures analysis of variance revealed a sig-
niﬁcant time effect (F4, 176 ¼ 8.8, P < 0.001), group effect (F5, 46 ¼ 10.7, P < 0.001), and a time by group interaction (F19, 176 ¼ 3.0, P < 0.001). (B) Dose-dependent increase of Max-
induced nociceptive behaviors. The cumulative number of events was summed over 30 min period of observation. I.t. administration of VIP (100 pmol) was without an effect.
Statistical analysis using one-way analysis of variance revealed a signiﬁcant group effect (F5, 46 ¼ 10.7, P < 0.001). (C) Effect of coadministration of max.d.4 (100 pmol) on Max
(50 pmol) or PACAP (100 pmol)-induced nociceptive responses. I.t. administration of max.d.4 (100 pmol) alone had no effect. (D) Effect of i.t. injection of max.d.4 (50 pmol) 10 min
after Max (25 pmol) injection on Max-induced nociceptive behaviors. Vertical arrow indicates i.t. administration of max.d.4 or vehicle. The number of events was counted every
1 min after the i.t. injection. Statistical analysis using one-way repeated-measures analysis of variance revealed a signiﬁcant time effect (F5, 48 ¼ 3.5, P < 0.01). *P < 0.05, **P < 0.01,
and ***P < 0.001, when compared with vehicle control (A, B) (Dunnett's test). #P < 0.05, ##P < 0.01, and ###P < 0.001, when compared with vehicle þ PACAP or Max group (C), Max
/ vehicle group (D) (Student's unpaired t-test). +P < 0.05 and ++P < 0.01, when compared with pre-drug (at 10 min) data (D) (Dunnett's test).
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R-mediated, we examined the effect of a selective PAC1-R antago-
nist, max.d.4. The pretreatment of max.d.4 potently attenuated the
development of the Max- or PACAP-induced nociceptive behaviors
(Fig. 1C). The post-treatment of max.d.4 also transiently reversed
the Max-induced behaviors (Fig. 1D), although the application of
max.d.4 alone did not produce the aversive response.
Since PACAP is known to stimulate the production of cAMP in
several cultured cells (3), we tested the effects of a PKA inhibitor,
Rp-8-Br-cAMPS (27), on the Max-induced nociceptive behaviors.
Rp-8-Br-cAMPS (1 nmol) with Max (25 pmol) markedly inhibited
the Max-induced nociceptive behaviors, although the coadminis-
tration of a vehicle did not (vehicle þ Max, 1188.5 ± 387.6 counts/
30 min, n ¼ 10; Rp-8-Br-cAMPS þ Max, 239.5 ± 106.3 counts/
30 min, n ¼ 10, P < 0.05, Student's unpaired t-test).
3.2. Maxadilan induces phosphorylation of extracellular signal-
regulated kinases in spinal dorsal horn
Extracellular signal-regulated kinase 1 (ERK1) and ERK2, also
referred to as p44 and p42 mitogen-activated protein kinase(MAPK), respectively, belong to a group of evolutionarily conserved
serine/threonine protein kinases (28). Early studies indicated a
critical role of ERK in regulating mitosis, proliferation, differentia-
tion, and survival of mammalian cells during development (29).
Phosphorylation of ERK has been extensively utilized as an indi-
cator of ERK activation, and recent evidence suggested that the
increment of phosphorylated ERK (pERK) in the spinal dorsal horn
neurons is nociceptive-speciﬁc and serves as a marker for central
sensitization, which is involved in pain hypersensitivity, following
persistent nociceptive activity (30,31).
I.t. injection of Max (25 pmol) rapidly evoked pERK in the spinal
dorsal horn within 5 min corresponding to onset of the nociceptive
behaviors (Fig. 2A). ERK phosphorylation by Max (50 pmol) was
also conﬁrmed by western blot analysis (Fig. 2B and C). Further-
more, Max signiﬁcantly increased both pERK1 and pERK2 in the
spinal cord at 5 min corresponding to the onset of the aversive
behaviors and at 30min corresponding to the plateau, although any
signiﬁcant change on the level of total ERK was veriﬁed neither for
ERK1 nor for ERK2.
ERK1/2 is activated by dual phosphorylation on their regulatory
tyrosine and threonine residues by its upstream kinase, MAPK/ERK
Fig. 2. Effect of Max on ERK activation in the spinal cord. (A) Representative immunohistochemistry of phosphorylated form of ERK (pERK) in the L5 spinal cord dorsal horn 5 min
after i.t. injection of Max (25 pmol). (B) pERK1/2 and total ERK1/2 from the spinal cords at 5 min after Max i.t. injection in Western blotting analysis. (C) pERK1/2 and total ERK1/2
from the spinal cords at 30 min after i.t. administration of Max and coadministration effect of a MEK inhibitor, PD98059 (2 nmol), or a JNK inhibitor, SP600125 (2 nmol) with Max
(50 pmol). b-actin was used as a control for sample loading. The pERK1/b-actin, pERK2/b-actin, ERK1/b-actin or ERK2/b-actin ratio of vehicle control was set at 1 for respective
quantiﬁcation. Fold changes of pERK1, pERK2, ERK1 and ERK2 were expressed as mean ± SEM (n ¼ 5 mice/group). (D) Effect of coadministration of PD98059 on Max-induced
nociceptive behaviors. The cumulative number of events was summed over 5 min bins of observation. *P < 0.05 and **P < 0.01, when compared with vehicle control;
++P < 0.01 and +++P < 0.001, when compared with Max 50 pmol; #P < 0.05 and ##P < 0.01, when compared with Max þ vehicle (Student's unpaired t-test).
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induction of nociceptive behaviors by Max, we co-administrated an
MEK inhibitor, PD98059 (32), and found that PD98059 (2 nmol)
signiﬁcantly blocked the phosphorylation of ERKs (Fig. 2C). As
mentioned later, it should be interesting that a JNK inhibitor,
SP600125 (2 nmol) also attenuated the Max-induced spinal ERK
activation at 30 min (Fig. 2C). In addition, PD98059 signiﬁcantly
reduced the Max-induced nociceptive behaviors, although the
vehicle did not (Fig. 2D).
3.3. Activation of spinal astroglial cells following i.t. administration
of maxadilan
Recently it has been suggested that the astroglial activation in
the spinal dorsal horn was associated with persistence of chronic
pain (33e37). In addition, previous in vitro and in vivo studies
demonstrated that astrocytes possess PAC1-R (38e41). Thus, to
examine whether Max-induced nociceptive behaviors were
accompanied by the spinal astroglial activation, we evaluated in-
tensity of immunoreactivity of an astrocyte marker, glial ﬁbrillary
acid protein (GFAP) at onset and plateau phase (5 and 30 min after
i.t. administration, respectively) of the behaviors.
In the vehicle treated spinal dorsal horn, the GFAP immuno-
staining was relatively low at both 5 and 30 min after the i.t.
administration (Fig. 3A and B). In contrast, the GFAP immunore-
activity was signiﬁcantly increased at 30 min but not 5 min after i.t.
injection of Max (25 pmol) (Fig. 3A and B). Western blot analysis
also demonstrated the upregulation of GFAP expression at 30 min
but not 5 min after i.t. administration of Max (50 pmol) (Fig. 3C and
D), suggesting that spinal astrocytes were signiﬁcantly activated
within 30 min by the stimulation of PAC1-R signaling pathway.
3.4. An astroglial toxin, L-a-aminoadipate blocks the development
of the maxadilan-induced nociceptive behaviors and ERK activation
In order to examine whether spinal astrocyte activation is
involved in the Max-induced nociceptive behaviors, we co-Fig. 3. Induction of spinal astroglial activation by Max. Representative glial ﬁbrillary acid p
5 min (A) and 30 min (B) after i.t. administration of Max (25 pmol). Western blot analyses s
Max (50 pmol), respectively. b-actin was used as a control for sample loading. GFAP to b-actin
as mean ± SEM (n ¼ 8e12 mice/group). ***P < 0.001, when compared with the effect of veadministrated L-a-aminoadipate (L-a-AA) at the dose of 0.3 and
1 nmol with Max (50 pmol). L-a-AA is reported as a cytotoxin
relatively speciﬁc for astrocytes, (34,42e45).
L-a-AA potently inhibited the Max-induced nociceptive re-
sponses, although simultaneous injection of the vehicle with Max
did not (Fig. 4A). Immunohistochemistry and western blotting
analysis demonstrated that L-a-AA (1 nmol) also attenuated Max
(50 pmol)-induced spinal ERK activation at 30 min (Fig. 4B and C).
However, the expression levels of total ERK (ERK1 and ERK2) were
not changed after the administration of Max with or without L-a-
AA.3.5. Activation of JNK in the spinal cord contributes to the
maxadilan-induced nociceptive behaviors
Like other MAP kinases, c-Jun N-terminal kinase (JNK) subfamily
is activated by phosphorylation (28, 31). Of the three isoforms of
JNK (JNK1, JNK2 and JNK3), JNK1 and JNK2 are abundantly
expressed in the spinal cord (31, 34, 46, 47), and JNK1 isoform is
mainly phosphorylated in the spinal astrocytes by peripheral nerve
injury or inﬂammation (34, 44,46e48). Thus, we examined
whether spinal injection of Max-induced JNK activation or not.
Thirty min after the i.t. administration of Max (50 pmol), the
expression levels of both phosphorylated forms of JNK1 and JNK2
(pJNK1 and pJNK2) were signiﬁcantly upregulated, but not 5 min
after the injection (Fig. 5A and B). In addition, we also found that
the Max-induced JNK activation was signiﬁcantly prevented by
coadministration of the MEK inhibitor, PD98059 (2 nmol) (Fig. 5B),
although the expression levels of total JNK (JNK1 and JNK2) were
not changed after the administration of Max with or without
PD98059.
To determine whether spinal JNK activation is involved in Max-
induced nociceptive behaviors or not, we intrathecally co-admin-
istrated a JNK inhibitor, SP600125 (2 nmol) (49), with Max.
SP600125markedly inhibited the development of theMax-induced
nociceptive behaviors, although the vehicle did not (Fig. 5C).rotein (GFAP) immunoﬂuorescence photomicrographs from the spinal cord sections at
howing the expression levels of GFAP at 5 min (C) and 30 min (D) after i.t. injection of
ratio of vehicle control was set at 1 for quantiﬁcation. Fold change of GFAP is expressed
hicle control (Student's unpaired t-test).
Fig. 4. Effect of an astroglial toxin, L-a-aminoadipate (L-a-AA) on the Max-induced nociceptive behaviors and ERK activation. (A) Effect of coadministration of L-a-AA (0.3 and
1 nmol) on the Max-induced nociceptive behaviors. The cumulative number of events was summed over 5 min bins of observation. Statistical analysis using two-way repeated-
measures analysis of variance revealed a signiﬁcant time effect (F2, 42 ¼ 39.7, P < 0.001), group effect (F2, 15 ¼ 60.6, P < 0.001), and a time by group interaction (F6, 42 ¼ 20.9,
P < 0.001). (B) Representative pERK immunoﬂuorescence staining in the L5 spinal cord dorsal horn 30 min after i.t. injection of Max (50 pmol) with or without L-a-AA (1 nmol). (C)
Western blot analyses for pERK1/2 and total ERK1/2 from the spinal cords at 30 min after i.t. injection of Max (50 pmol) with or without L-a-AA (1 nmol). b-actin was used as a
control for sample loading. The pERK1/b-actin, pERK2/b-actin, ERK1/b-actin or ERK2/b-actin ratio of vehicle control was set at 1 for respective quantiﬁcation. Fold changes of pERK1,
pERK2, ERK1 and ERK2 were expressed as mean ± SEM (n ¼ 6 mice/group). **P < 0.01, ***P < 0.001, when compared with Max þ vehicle control group (Dunnett's test). +P < 0.05,
++P < 0.01, when compared with vehicle control; #P < 0.05 and ##P < 0.01, when compared with Max 50 pmol (Student's unpaired t-test).
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In this study, we have explored the pharmacological character-
ization of Max-induced nociception and suggested that: (1) The
nociception was initiated by PKA-ERK signaling via PAC1-R on the
dorsal horn neurons; (2) The upregulation of GFAP protein
expression and JNK activation indicating astroglial activation
occurred in the downstream of activation of ERK signaling; (3) In
turn, the astroglial activation maintained the neuronal ERK acti-
vation. These ﬁndings imply that spinal PACAP-PAC1-R signaling
may activate a positive feedback circuit for neuronaleastroglial
interaction to induce and maintain nociception (Fig. 6).4.1. Spinal PAC1 receptor activation and nociceptive behaviors
In the present study, we showed that the i.t. injection of selec-
tive PAC1-R agonist, Max, gradually induced and maintained the
nociceptive behaviors, which were similar to those of PACAP as
previously reported (20). Further, coadministration of speciﬁc
PAC1-R antagonist, max.d.4 attenuated the development (both the
onset and the plateau) of Max-induced aversive responses. In
support of the experiments mentioned above, it has been reported
that conventional PAC1-R knockout mice signiﬁcantly reduced
nociception of late phase in the formalin test (50). In contrast to
Max, VIP, which is a selective agonist for VPAC1- and VPAC2-R but
not for PAC1-R (3,4), hardly induced nociceptive behaviors in
agreement with previous studies (51,52). Thus, it was suggested
that spinal PAC1-R signaling is crucial for the induction and main-
tenance of PACAP- or Max-induced nociception.Next, we showed that a PKA inhibitor, Rp-8-Br-cAMPS signiﬁ-
cantly suppressed the Max-induced nociceptive behaviors for
30 min after the i.t. injection. Since PAC1-R signaling is mediated
through PKA- and/or PLC-signaling cascades on the various type of
cultured cells including neurons and astrocytes (39,53e56), it is
speculated that in mouse spinal cord PKA-signaling cascade in the
downstream of PACAP-PAC1-R signaling is associated with the
nociception. As a result, the PKA inhibitor signiﬁcantly suppressed
the nociceptive behaviors during the observed period. However, we
could not exclude the possibility that PLC-signaling might also
contribute to the aversive behaviors, and it needs further studies to
evaluate the association between PLC-signaling and the
nociception.4.2. Nociceptive behaviors by PAC1 receptor activation and ERK
phosphorylation
A growing body of evidence demonstrates that ERK phos-
phorylation (activation) plays a crucial role in pain plasticity and
hypersensitivity (31). It is generally believed that ERK phos-
phorylation in the spinal cord is only induced by high-threshold
noxious stimuli (but not by innoxious stimuli), and pERK is
speciﬁcally localized in dorsal horn neurons immediately after
peripheral neuropathy or inﬂammation (31,57,58). PAC1-R is also
reported to be mainly localized in neurons of spinal cord by in
situ hybridization histochemistry (6), although the detailed
signaling mechanisms in the downstream of PAC1-R activation in
spinal cord are unknown. The previous studies demonstrated
that the activation of several protein kinases including PKA
Fig. 5. I.t. Max activates JNK in the spinal cord. (A, B) Representative western blots for pJNK1/2 and total JNK1/2 from the spinal cords at 5 min (A; left panel) and 30 min (B; left
panel) after i.t. injection of vehicle (), Max (50 pmol), or coadministration of a MEK inhibitor, PD98059 (2 nmol) with Max (50 pmol). Max-induced increases in levels of
phosphorylated form of JNK1 (pJNK1) and pJNK2 are blocked by i.t. coadministration of PD98059 at 30 min after i.t. injection (B). b-actin was used as a control for sample loading.
The pJNK1/b-actin, pJNK2/b-actin, JNK1/b-actin or JNK2/b-actin ratio of vehicle control was set at 1 for quantiﬁcation. Fold changes of pJNK1, pJNK2, JNK1 and JNK2, expressed as
mean ± SEM (n ¼ 5 mice/group), were shown in (A; middle and right panels) and (B; middle and right panels). (C) I.t. coadministration of a JNK inhibitor, SP600125, with Max
reduced the expression of nociceptive behaviors. The cumulative number of events was summed over 5 min bins of observation. *P < 0.05, and **P < 0.01, when compared with
vehicle control; ++P < 0.01 and +++P < 0.001, when compared with Max þ vehicle; #P < 0.05 and ##P < 0.01, when compared with Max 50 pmol (Student's unpaired t-test).
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(59e62). These lead us to speculate that PAC1-R activation
induced ERK phosphorylation in the spinal dorsal horn neurons.
The immunochemistry and western blot analysis demonstrated
that Max augmented pERK as early as at 5 min and lasted more
than 30 min after the i.t. injection. Further, an MEK inhibitor,
PD98059 inhibited the development of Max-induced nociceptive
behaviors. These ﬁndings suggest that PAC1-R in spinal neurons
contributed to the development of the nociception through the
ERK activation.4.3. The contribution of astrocytes to maxadilan-induced
nociceptive responses
Regarding the genesis and maintenance of inﬂammatory and
neuropathic pain, recent progresses also focus on the critical role of
glial cells, especially microglia and astrocytes, in the spinal cord and
brain (33e37,63,64). As compared to microglial activation,astroglial activation is generally considered to be more persistent
and plays a more important role during the maintenance phase of
chronic pain such as neuropathic pain. For example, the activation
of astrocytes as a result of peripheral neuropathy is shown to occur
about 4 days after nerve injury and persists until the at least four-
weeks post-injury, suggesting the involvement of astrocytes in the
maintenance of pain (64e67). Furthermore, the inhibition of
astroglial function by ﬂuorocitrate or L-a-AA was shown to atten-
uate nerve injury- or inﬂammation-induced mechanical allodynia
(34,44,45).
In this study, we have shown that Max markedly upregulated
GFAP expression, which indicates astroglial activation (33,35,64), at
30 min after the i.t. injection. Furthermore, coadministration of L-a-
AA remarkably attenuated the development of nociceptive behav-
iors induced by Max. These suggest the importance of astroglial
activation in the PACAP-PAC1-R signaling-induced nociception.
Since spinal PACAP-PAC1-R signaling-induced GFAP later than
pERK, it was suggested that the activation of astrocyte would be
Fig. 6. Schematic diagram showing a hypothetical mechanism for how spinal PAC1-R
activation induces long-lasting spontaneous nociceptive behaviors. Intrathecal injec-
tion of Max stimulates PAC1-R on spinal dorsal horn neurons and causes immediate
activation of ERK, although we cannot completely negate possible rapid and direct
activation of dorsal horn astrocytes (①). ERK activation is followed by synthesis and
release of some communicator molecules, which trigger astroglial activation including
JNK activation (②). Activated astrocytes also produce some signaling molecules, which
in turn facilitate neuronal activity including maintenance of ERK activation (③),
contributing to enhanced spontaneous nociceptive behaviors.
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direct effect through astroglial PAC1-R. However, it may be worth
noting here that L-a-AA blocked the induction of the aversive
response frommuch earlier time bins. Although further studies are
necessary to approve, we speculate that Max might induce rela-
tively rapid astroglial activation, which contributes to the induction
of the nociceptive behaviors, before signiﬁcant GFAP upregulation,
and L-a-AA might interfere with this process.
There are several reports to describe an acute increase in GFAP
expression as soon as 0.5e1 h after electrical stimulation of primary
afferents and injection of complete Freund's adjuvant or snake
venom components (68,69). The rapid induction of GFAP may be
attributed to translational regulation. Thus, regarding the interac-
tion between neurons and astrocytes, further study to identify the
mediators from neurons to astrocytes through spinal PACAP-PAC1-
R signaling should be required.4.4. Involvement of JNK phosphorylation (activation) in maxadilan-
induced nociceptive behaviors
JNK is suggested to be an important intracellular MAP kinase in
spinal astrocytes in chronic pain. Previous studies showed that
spinal inhibition of JNK by its inhibitor, SP600125 or D-JNKI-1, can
prevent and reverse inﬂammation- or nerve injury-induced me-
chanical allodynia. (31,44e47). As mentioned in the case of pERK, it
would also be reasonable to speculate that JNK is activated in as-
trocytes by Max administration.
In our present study, Max increased pJNK at 30 min but not
5 min after the i.t. administration, and pJNK1 levels were more
pronounced than pJNK2 levels in the Max-treated groups. In
addition, a JNK inhibitor, SP600125, signiﬁcantly attenuated the
development of the Max-induced nociceptive behaviors. These
results may be in line with previous reports showing that JNK
contributes pain hypersensitivity, and JNK1 is the major isoform
activated in the spinal cord by peripheral inﬂammation or nerve
injury (31, 44, 46).4.5. Interaction between neurons and astrocytes in spinal cord for
nociceptive behaviors
While the ERK phosphorylation occurred within 5 min after
Max i.t. injection, signiﬁcant JNK phosphorylation and upregulation
of GFAP appeared at 30min but not 5min after Max administration.
In addition, the MEK inhibitor, PD98059, inhibited the Max-
induced JNK phosphorylation. These results suggest that the ERK
phosphorylation may be necessary for the JNK phosphorylation.
Intriguingly, our results also showed that the Max-induced ERK
phosphorylation was abrogated either by the astroglial toxin, L-a-
AA, or the JNK inhibitor, SP600125. These suggest a crucial role of
astroglial activation through the interaction of neurons and astro-
cytes for the persistent nociceptive behaviors. Regarding the effect
of astroglial JNK activation on the ERK phosphorylation in dorsal
horn neurons, it is well known that JNK phosphorylates a wide
range of substrates and affect on numerous cell responses,
including production of inﬂammatory mediators such as nitric
oxide, interleukins, chemokines and so on (31,34e37,47,64). In or-
der to clarify what mediator between astrocytes and neurons is
actually involved in the ERK phosphorylation, further extensive
studies should be required.
Taken together, spinal astrocytes play a signiﬁcant role in
mediating the PAC1-R-induced nociceptive behaviors by main-
taining the ERK signaling pathway in the dorsal horn neurons,
although the underlying mechanisms remain to be determined.
Thus, present study indicates that spinal PAC1-R signaling pathway
is an important regulator of astroglial activation in terms of pain
transmission and proposes that targeting PAC1-R signaling pathway
may provide a new avenue for pain therapy.
5. Conclusions
We have shown that in the spinal cord PACAP-PAC1-R signaling
pathway regulates the nociception through the interaction of
neurons and astrocytes by activation of ERK or JNK each other. This
linkage between PAC1-R and astroglial activation in nociception
may offer a new option to treat intractable chronic pain.
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